CMMB Chemomab Therapeutics Ltd. ADRs
Chemomab is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. Chemomab is currently testing CM-101 in three phase 2 studies focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc) This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$1.58 -0.03 (-1.86%)
As of 03/27/2023 10:02:55 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Israel
Country of incorporation:
IPO date: 02/12/2019
Outstanding shares: 220,996,240
Average volume: 98,526
Market cap: $349,174,059
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%